CRON Fundamental Analysis - CRONOS GROUP INC

Fundamental Rating

Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 34 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.

In the past year CRON had a positive cash flow from operations.

CRON had negative earnings in 4 of the past 5 years.

In the past 5 years CRON reported 4 times negative operating cash flow.

1.2 Ratios

CRON's Return On Assets of 1.57% is amongst the best of the industry. CRON outperforms 85.29% of its industry peers.

The Return On Equity of CRON (1.71%) is better than 82.35% of its industry peers.

		Industry Rank	Sector Rank
ROA	1.57%
ROE	1.71%
ROIC	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 14.19%, CRON belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.

In the last couple of years the Profit Margin of CRON has declined.

The Gross Margin of CRON (32.74%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	14.19%
GM	32.74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

CRON has more shares outstanding than it did 1 year ago.

The number of shares outstanding for CRON has been increased compared to 5 years ago.

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CRON has an Altman-Z score of 7.82. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

CRON has a Altman-Z score of 7.82. This is amongst the best in the industry. CRON outperforms 97.06% of its industry peers.

There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	7.82

ROIC/WACCN/A

WACC9.21%

2.3 Liquidity

CRON has a Current Ratio of 24.65. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

With an excellent Current ratio value of 24.65, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

CRON has a Quick Ratio of 23.53. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 23.53, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	24.65
Quick Ratio	23.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.50% over the past year.

CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.

Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 28.01%.

Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 37.71% on average per year.

EPS 1Y (TTM)162.5%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%-400%

Revenue 1Y (TTM)28.01%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%20.51%

3.2 Future

The Earnings Per Share is expected to decrease by -21.14% on average over the next years. This is quite bad

CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.39% yearly.

EPS Next Y-115.3%

EPS Next 2Y-15.5%

EPS Next 3Y3.91%

EPS Next 5Y-21.14%

Revenue Next Year12.95%

Revenue Next 2Y21.44%

Revenue Next 3Y7.49%

Revenue Next 5Y7.39%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 50.86 indicates a quite expensive valuation of CRON.

Based on the Price/Earnings ratio, CRON is valued a bit cheaper than 79.41% of the companies in the same industry.

CRON's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.08.

A Price/Forward Earnings ratio of 36.26 indicates a quite expensive valuation of CRON.

CRON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 73.53% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 22.72. CRON is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	50.86
Fwd PE	36.26

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-15.5%

EPS Next 3Y3.91%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

TSX:CRON (8/29/2025, 7:00:00 PM)

3.56

-0.01 (-0.28%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-07 2025-08-07/bmo

Earnings (Next)11-10 2025-11-10

Inst Owners13.12%

Inst Owner ChangeN/A

Ins Owners6.2%

Ins Owner ChangeN/A

Market Cap1.36B

Analysts80

Price Target2.4 (-32.58%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-0.26%

Min Revenue beat(2)-0.31%

Max Revenue beat(2)-0.21%

Revenue beat(4)1

Avg Revenue beat(4)-1.44%

Min Revenue beat(4)-14.99%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)1.96%

Revenue beat(12)4

Avg Revenue beat(12)-3.07%

Revenue beat(16)7

Avg Revenue beat(16)-2.54%

PT rev (1m)0%

PT rev (3m)-34.81%

EPS NQ rev (1m)100%

EPS NQ rev (3m)N/A

EPS NY rev (1m)65.38%

EPS NY rev (3m)65.38%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-7.23%

Revenue NY rev (1m)-6.25%

Revenue NY rev (3m)-4.63%

Valuation

		Industry Rank	Sector Rank
PE	50.86
Fwd PE	36.26
P/S	7.61
P/FCF	N/A
P/OCF	49.52
P/B	0.92
P/tB	0.99
EV/EBITDA	N/A

EPS(TTM)0.07

EY1.97%

EPS(NY)0.1

Fwd EY2.76%

FCF(TTM)-0.03

FCFYN/A

OCF(TTM)0.07

OCFY2.02%

SpS0.47

BVpS3.89

TBVpS3.61

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	1.57%
ROE	1.71%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	14.19%
GM	32.74%
FCFM	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	224.14%
Cap/Sales	22.6%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	24.65
Quick Ratio	23.53
Altman-Z	7.82

F-Score7

WACC9.21%

ROIC/WACCN/A

Cap/Depr(3y)70.04%

Cap/Depr(5y)158.35%

Cap/Sales(3y)6.62%

Cap/Sales(5y)22.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)162.5%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%-400%

EPS Next Y-115.3%

EPS Next 2Y-15.5%

EPS Next 3Y3.91%

EPS Next 5Y-21.14%

Revenue 1Y (TTM)28.01%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%20.51%

Revenue Next Year12.95%

Revenue Next 2Y21.44%

Revenue Next 3Y7.49%

Revenue Next 5Y7.39%

EBIT growth 1Y42.58%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year98.02%

EBIT Next 3Y27.54%

EBIT Next 5Y9.95%

FCF growth 1Y90.67%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y120.6%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens